Aura Biosciences Inc (AURA)

$5.26 +0.20 (3.95%)
Market Cap 321.96M
Revenue (ttm) 0.00
Net Income (ttm) -86.92M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 165,300
Avg Vol 198,138
Day's Range N/A - N/A
Shares Out 63.50M
Stochastic %K 30%
Beta 0.46
Analysts Strong Sell
Price Target $19.40

Company Profile

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 500 8864
Address:
80 Guest Street, 5th Floor, Boston, United States
garygb
garygb Jan. 5 at 8:55 PM
$AURA Excited about this one.
0 · Reply
garygb
garygb Jan. 5 at 5:33 PM
$AURA great entry spot
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 2 at 5:51 PM
$AURA Current Stock Price: $5.21 Contracts to trade: $5 AURA Jan 16 2026 Call Entry: $0.40 Exit: $0.58 ROI: 45% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
OnlyFibs
OnlyFibs Dec. 28 at 4:00 AM
$AURA back-tests its structural floor at $5.81. Between the Phase 3 CoMpass trial momentum and the 86% institutional anchor, the fundamental floor is completely disconnected from the current price. The Setup: Textbook 8h bottoming signs with surging buy volume. We need that final "push" through $6.11 to confirm the next leg up. Bull Level: A high-volume breakout targets the $23.00 max estimate. Bear Safety: The absolute Line in the Sand is $4.35. Break it and we’re out. Catalyst: Initial data from the mid-2026 bladder cancer trial is the next massive institutional trigger. 🚢📉 #hovdid
0 · Reply
GlobalNorthN
GlobalNorthN Dec. 25 at 2:54 PM
$AURA This ticker is entering a stage where execution quality will overshadow headline narratives. Margin stability needs to accompany any growth acceleration. Momentum becomes sustainable only with dependable execution. Patience is reasonable — but it must be matched by tangible progress.
0 · Reply
johsmith
johsmith Dec. 24 at 1:27 PM
$AURA Identified as buy candidate. Still waiting a bit. But great opportunity in my eyes.
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 11 at 8:58 PM
$AURA Share Price: $6.53 Contract Selected: Jul 17, 2026 $7.5 Calls Buy Zone: $0.51 – $0.63 Target Zone: $0.96 – $1.17 Potential Upside: 78% ROI Time to Expiration: 217 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
JarvisFlow
JarvisFlow Nov. 26 at 12:15 PM
Evercore ISI Group updates rating for Aura Biosciences ( $AURA ) to Outperform, target set at 13.
0 · Reply
BillionerOfKing
BillionerOfKing Oct. 14 at 2:05 PM
$AURA Current Stock Price: $6.08 Contracts to trade: $5 AURA Oct 17 2025 Call Entry: $1.71 Exit: $2.71 ROI: 58% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Buysellbkr
Buysellbkr Oct. 13 at 10:26 PM
$AURA lets get 1.50
1 · Reply
Latest News on AURA
Aura Biosciences to Participate in the 8th Annual Evercore Healthcare Conference

Nov 24, 2025, 4:05 PM EST - 7 weeks ago

Aura Biosciences to Participate in the 8th Annual Evercore Healthcare Conference

Aura Biosciences Reports Third Quarter 2025 Financial Results and Business Highlights

Nov 13, 2025, 7:00 AM EST - 2 months ago

Aura Biosciences Reports Third Quarter 2025 Financial Results and Business Highlights

Aura Biosciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 7:00 AM EDT - 4 months ago

Aura Biosciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aura Biosciences Reports Second Quarter 2025 Financial Results and Business Highlights

Aug 13, 2025, 7:00 AM EDT - 5 months ago

Aura Biosciences Reports Second Quarter 2025 Financial Results and Business Highlights

Aura Biosciences Announces Pricing of Public Offering of Common Stock and Warrants

May 15, 2025, 9:32 AM EDT - 8 months ago

Aura Biosciences Announces Pricing of Public Offering of Common Stock and Warrants

Aura Biosciences Announces Proposed Public Offering of Common Stock and Warrants

May 15, 2025, 6:10 AM EDT - 8 months ago

Aura Biosciences Announces Proposed Public Offering of Common Stock and Warrants

Aura Biosciences Reports First Quarter 2025 Financial Results and Business Highlights

May 15, 2025, 6:01 AM EDT - 8 months ago

Aura Biosciences Reports First Quarter 2025 Financial Results and Business Highlights

Aura Biosciences to Participate in Upcoming Investor Conferences

May 1, 2025, 4:01 PM EDT - 9 months ago

Aura Biosciences to Participate in Upcoming Investor Conferences

Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors

Apr 2, 2025, 7:00 AM EDT - 10 months ago

Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors

Aura Biosciences, Inc (AURA) Virtual Urologic Oncology Investor Event Call (Transcript)

Mar 25, 2025, 6:58 PM EDT - 10 months ago

Aura Biosciences, Inc (AURA) Virtual Urologic Oncology Investor Event Call (Transcript)

Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Mar 24, 2025, 4:01 PM EDT - 10 months ago

Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Positive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress

Mar 24, 2025, 7:00 AM EDT - 10 months ago

Positive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress

Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urology Congress

Mar 3, 2025, 7:00 AM EST - 11 months ago

Aura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urology Congress

Muscle Invasive Bladder Cancer Drug Pipeline Market Research 2024 Featuring Aura Biosciences, Janssen Research & Development, Asieris Pharmaceuticals, and RemeGen

Dec 2, 2024, 4:31 AM EST - 1 year ago

Muscle Invasive Bladder Cancer Drug Pipeline Market Research 2024 Featuring Aura Biosciences, Janssen Research & Development, Asieris Pharmaceuticals, and RemeGen

Aura Biosciences: 2 Positive Bel-Sar Data Releases Brings Shareholder Value

Oct 21, 2024, 3:12 PM EDT - 1 year ago

Aura Biosciences: 2 Positive Bel-Sar Data Releases Brings Shareholder Value

Aura Biosciences' Bladder Cancer Candidate Demonstrates Tumor Shrinkage In Patients With High-Grade Disease

Oct 18, 2024, 9:16 AM EDT - 1 year ago

Aura Biosciences' Bladder Cancer Candidate Demonstrates Tumor Shrinkage In Patients With High-Grade Disease

Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial

Oct 17, 2024, 4:05 PM EDT - 1 year ago

Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial

3 Small-Cap Stocks Ready to Deliver Significant Growth

Oct 15, 2024, 12:40 PM EDT - 1 year ago

3 Small-Cap Stocks Ready to Deliver Significant Growth

FBRT TZOO

Sept. 13-20 Undercovered Stock Picks: Aura Biosciences, APA Corporation, iTeos, CuriosityStream +

Sep 20, 2024, 3:30 PM EDT - 1 year ago

Sept. 13-20 Undercovered Stock Picks: Aura Biosciences, APA Corporation, iTeos, CuriosityStream +

APA CURI

Aura Biosciences: Highly Derisked Late-Stage Eye Cancer Company

Sep 17, 2024, 12:31 PM EDT - 1 year ago

Aura Biosciences: Highly Derisked Late-Stage Eye Cancer Company

Aura Biosciences Touts Promising Data From Eye Cancer Candidate

Sep 12, 2024, 11:40 AM EDT - 1 year ago

Aura Biosciences Touts Promising Data From Eye Cancer Candidate

Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma

Sep 12, 2024, 6:30 AM EDT - 1 year ago

Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma

Aura Biosciences to Host a Urologic Oncology Investor Event to Present Early Non-Muscle Invasive Bladder Cancer (NMIBC) Data from its Ongoing Phase 1 Trial on Thursday, October 17, 2024

Sep 3, 2024, 4:05 PM EDT - 1 year ago

Aura Biosciences to Host a Urologic Oncology Investor Event to Present Early Non-Muscle Invasive Bladder Cancer (NMIBC) Data from its Ongoing Phase 1 Trial on Thursday, October 17, 2024

Aura Biosciences Announces the Presentation of Phase 2 End of Study Data Evaluating Suprachoroidal Administration of Bel-sar for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at The Retina Society Annual Meeting

Aug 26, 2024, 4:05 PM EDT - 1 year ago

Aura Biosciences Announces the Presentation of Phase 2 End of Study Data Evaluating Suprachoroidal Administration of Bel-sar for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at The Retina Society Annual Meeting

Aura Biosciences Reports Second Quarter 2024 Financial Results and Business Highlights

Aug 8, 2024, 7:00 AM EDT - 1 year ago

Aura Biosciences Reports Second Quarter 2024 Financial Results and Business Highlights

Aura Biosciences to Participate in the Jefferies Global Healthcare Conference

May 30, 2024, 4:05 PM EDT - 1 year ago

Aura Biosciences to Participate in the Jefferies Global Healthcare Conference

Aura Biosciences to Host Virtual KOL Event “Pioneering a New Standard of Care In Ocular Oncology” on May 29, 2024

May 23, 2024, 8:00 AM EDT - 1 year ago

Aura Biosciences to Host Virtual KOL Event “Pioneering a New Standard of Care In Ocular Oncology” on May 29, 2024

Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights

May 9, 2024, 7:00 AM EDT - 1 year ago

Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights

Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Mar 27, 2024, 7:00 AM EDT - 1 year ago

Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal Melanoma

Dec 7, 2023, 8:00 AM EST - 2 years ago

Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal Melanoma

Aura Biosciences: Mid-2024 Data Could Bring Expansion Opportunity

Nov 15, 2023, 8:23 AM EST - 2 years ago

Aura Biosciences: Mid-2024 Data Could Bring Expansion Opportunity

Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

Nov 9, 2023, 4:05 PM EST - 2 years ago

Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

Aura Biosciences Announces Pricing of Public Offering of Common Stock

Nov 6, 2023, 10:02 PM EST - 2 years ago

Aura Biosciences Announces Pricing of Public Offering of Common Stock

Aura Biosciences Announces Proposed Public Offering of Common Stock

Nov 6, 2023, 4:08 PM EST - 2 years ago

Aura Biosciences Announces Proposed Public Offering of Common Stock

Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal Melanoma

Nov 6, 2023, 3:00 PM EST - 2 years ago

Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal Melanoma

Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023

Oct 31, 2023, 4:05 PM EDT - 2 years ago

Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023

Aura Biosciences Strengthens and Expands Leadership Team with Key Appointments

Oct 2, 2023, 4:05 PM EDT - 2 years ago

Aura Biosciences Strengthens and Expands Leadership Team with Key Appointments

Aura Biosciences Reports Second Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

Aug 9, 2023, 7:00 AM EDT - 2 years ago

Aura Biosciences Reports Second Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

Aura Biosciences: Excellent Execution In The Large Ocular Cancer Market

May 27, 2023, 8:00 AM EDT - 2 years ago

Aura Biosciences: Excellent Execution In The Large Ocular Cancer Market

Aura Biosciences to Participate in the JMP Securities Life Sciences Conference

May 12, 2023, 7:00 AM EDT - 2 years ago

Aura Biosciences to Participate in the JMP Securities Life Sciences Conference

Aura Biosciences Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

May 11, 2023, 4:10 PM EDT - 2 years ago

Aura Biosciences Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights

Mar 15, 2023, 4:10 PM EDT - 3 years ago

Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights

Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administration

Feb 16, 2023, 7:00 AM EST - 3 years ago

Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administration

Aura Biosciences Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

Nov 10, 2022, 7:00 AM EST - 3 years ago

Aura Biosciences Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

Aura Announces Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan in Early-Stage Choroidal Melanoma

Nov 10, 2022, 6:45 AM EST - 3 years ago

Aura Announces Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan in Early-Stage Choroidal Melanoma

Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma Presented at AAO 2022

Oct 3, 2022, 7:00 AM EDT - 3 years ago

Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma Presented at AAO 2022

Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer

Sep 28, 2022, 7:00 AM EDT - 3 years ago

Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer

Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2022

Sep 27, 2022, 7:00 AM EDT - 3 years ago

Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2022

Aura Biosciences to Present Phase 2 Safety Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) in Patients with Choroidal Melanoma at the ESMO 2022 Congress

Sep 7, 2022, 7:00 AM EDT - 3 years ago

Aura Biosciences to Present Phase 2 Safety Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) in Patients with Choroidal Melanoma at the ESMO 2022 Congress

Aura Biosciences to Present Belzupacap Sarotalocan (AU-011) Data from Multiple Studies at the 22nd EURETINA Congress

Sep 1, 2022, 7:00 AM EDT - 3 years ago

Aura Biosciences to Present Belzupacap Sarotalocan (AU-011) Data from Multiple Studies at the 22nd EURETINA Congress

garygb
garygb Jan. 5 at 8:55 PM
$AURA Excited about this one.
0 · Reply
garygb
garygb Jan. 5 at 5:33 PM
$AURA great entry spot
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 2 at 5:51 PM
$AURA Current Stock Price: $5.21 Contracts to trade: $5 AURA Jan 16 2026 Call Entry: $0.40 Exit: $0.58 ROI: 45% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
OnlyFibs
OnlyFibs Dec. 28 at 4:00 AM
$AURA back-tests its structural floor at $5.81. Between the Phase 3 CoMpass trial momentum and the 86% institutional anchor, the fundamental floor is completely disconnected from the current price. The Setup: Textbook 8h bottoming signs with surging buy volume. We need that final "push" through $6.11 to confirm the next leg up. Bull Level: A high-volume breakout targets the $23.00 max estimate. Bear Safety: The absolute Line in the Sand is $4.35. Break it and we’re out. Catalyst: Initial data from the mid-2026 bladder cancer trial is the next massive institutional trigger. 🚢📉 #hovdid
0 · Reply
GlobalNorthN
GlobalNorthN Dec. 25 at 2:54 PM
$AURA This ticker is entering a stage where execution quality will overshadow headline narratives. Margin stability needs to accompany any growth acceleration. Momentum becomes sustainable only with dependable execution. Patience is reasonable — but it must be matched by tangible progress.
0 · Reply
johsmith
johsmith Dec. 24 at 1:27 PM
$AURA Identified as buy candidate. Still waiting a bit. But great opportunity in my eyes.
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 11 at 8:58 PM
$AURA Share Price: $6.53 Contract Selected: Jul 17, 2026 $7.5 Calls Buy Zone: $0.51 – $0.63 Target Zone: $0.96 – $1.17 Potential Upside: 78% ROI Time to Expiration: 217 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
JarvisFlow
JarvisFlow Nov. 26 at 12:15 PM
Evercore ISI Group updates rating for Aura Biosciences ( $AURA ) to Outperform, target set at 13.
0 · Reply
BillionerOfKing
BillionerOfKing Oct. 14 at 2:05 PM
$AURA Current Stock Price: $6.08 Contracts to trade: $5 AURA Oct 17 2025 Call Entry: $1.71 Exit: $2.71 ROI: 58% Hold ~20 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Buysellbkr
Buysellbkr Oct. 13 at 10:26 PM
$AURA lets get 1.50
1 · Reply
BillionerOfKing
BillionerOfKing Oct. 9 at 10:25 AM
$AURA Current Stock Price: $6.08 Contracts to trade: $5 AURA Oct 17 2025 Call Entry: $1.71 Exit: $3.39 ROI: 98% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Quantumup
Quantumup Oct. 7 at 12:18 PM
Citizens reiterated $IDYA Market Outperform-$45 and said, 'We Remain Bullish On IDYA's Upcoming ESMO Update That Can Help Investors To Estimate The PoS Of The Neoadjuvant Uveal Melanoma Opportunity.' $IMCR $AURA Citizens additionally said:
0 · Reply
Sillyspuh
Sillyspuh Oct. 2 at 7:56 PM
$AURA sleepy stock. will it ever wake up?
1 · Reply
WickRange
WickRange Aug. 23 at 6:22 AM
$AURA Aura Biosciences is a clinical stage oncology company with novel virus-like drug conjugate platform
0 · Reply
d_risk
d_risk Aug. 13 at 4:01 PM
$AURA - Aura Biosciences Inc. Common Stock - 10Q - Updated Risk Factors Aura’s latest 10-Q risk factors spotlight expanded challenges in bel-sar’s development, regulatory hurdles, and commercialization, heightened funding and dilution risks, new cybersecurity and disaster threats, increased operational and litigation exposures, and reduced insider control—underscoring deep financial and execution uncertainties ahead. #Biotechnology #OperationalRisk #Cybersecurity #FundingRisk #RegulatoryRisk 🟢 Added 🟠 Removed https://d-risk.ai/AURA/10-Q/2025-08-13
0 · Reply
Freddie___Mac
Freddie___Mac Jul. 14 at 9:44 PM
$EYPT we are moving in the right direction... stock is up nicely since then. two under the radar names I recommend to look at are $DRTS and $AURA
2 · Reply
jayz_crypto
jayz_crypto Jul. 12 at 12:41 PM
$USELESS.X Useless aura $USERA JUST LAUNCHED ON PUMP.FUN THIS ONE BUILDING IN SILENCE Get in before dex and boost is paid at 20k 2 of the most hottest meme $USELESS and $AURA LOW MC 7K, GREAT ENTRY. GRAB A MOON BAG AND SEE WHAT HAPPENS. TEAM VERY ACTIVE AND MEMES AND ART ARE FIRE. DcHhSnBjmpE3iCnoeCfpqQKFfp8r7rxE5d7Tm26tpump https://dexscreener.com/solana/3MJsCbu7WbCp2xsDAQVQQruNi7oX9M4VKAWb9LnKYQmQ
0 · Reply
ExitSTRATjoe77
ExitSTRATjoe77 Jun. 18 at 7:30 PM
$AURA
0 · Reply
rando321456
rando321456 Jun. 18 at 8:01 AM
$CLSD $AURA It was a few weeks ago but when Aura's ceo was talking about pricing they referenced the approved drug for the choroidal melanoma that has spread, which goes for about 600k before the patient dies. Am I off my rocker thinking that between choroidal melanoma and mets that they will just be doing 5 billion dollars in revenue if the data pattern holds?
1 · Reply
JarvisFlow
JarvisFlow Jun. 2 at 6:57 PM
JMP Securities has updated their rating for Aura Biosciences ( $AURA ) to Market Outperform with a price target of 19.
0 · Reply
JarvisFlow
JarvisFlow May. 23 at 1:23 PM
JMP Securities has updated their rating for Aura Biosciences ( $AURA ) to Market Outperform with a price target of 19.
0 · Reply
AZOZ
AZOZ May. 21 at 12:03 PM
$PAPL $RLMD $PSQH $AURA Insider's love it right now!
0 · Reply